Identification of substances formed by decomposition of peak E substance in tryptophan
- PMID:1544609
- DOI: 10.1016/0278-6915(92)90139-c
Identification of substances formed by decomposition of peak E substance in tryptophan
Abstract
Peak E substance, a trace impurity in L-tryptophan, has been associated epidemiologically with an outbreak of eosinophilia-myalgia syndrome (EMS) in the USA in 1989. After fractionation and purification of this substance, nuclear magnetic resonance and fast-atom-bombardment mass spectroscopy were used to identify the molecular structures of peak X/X' (formed by the decomposition of peak E substance in a simulated gastric fluid) and peak Y/Y' substances (which are believed to be the intermediates in the transformation of peak E substance to peak X/X' substances). The analyses were also performed on synthesized peak E substance obtained from the reaction of tryptophan with acetaldehyde. The results indicated that the synthesized substance was of high purity and was suitable for use in studies investigating the relationship between peak E substance and EMS onset.
Similar articles
- Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.Adachi J, Naito T, Ueno Y, Ogawa Y, Ninomiya I, Tatsuno Y.Adachi J, et al.Arch Toxicol. 1993;67(4):284-9. doi: 10.1007/BF01974348.Arch Toxicol. 1993.PMID:8517785
- Characterization of "peak E," a novel amino acid associated with eosinophilia-myalgia syndrome.Mayeno AN, Lin F, Foote CS, Loegering DA, Ames MM, Hedberg CW, Gleich GJ.Mayeno AN, et al.Science. 1990 Dec 21;250(4988):1707-8. doi: 10.1126/science.2270484.Science. 1990.PMID:2270484
- Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome.Klarskov K, Gagnon H, Boudreault PL, Normandin C, Plancq B, Marsault E, Gleich GJ, Naylor S.Klarskov K, et al.Toxicol Lett. 2018 Jan 5;282:71-80. doi: 10.1016/j.toxlet.2017.10.012. Epub 2017 Oct 14.Toxicol Lett. 2018.PMID:29037509
- L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.Varga J, Jimenez SA, Uitto J.Varga J, et al.J Invest Dermatol. 1993 Jan;100(1):97S-105S. doi: 10.1111/1523-1747.ep12356368.J Invest Dermatol. 1993.PMID:8423409Review.
- The cause and pathogenesis of the eosinophilia-myalgia syndrome.Varga J, Uitto J, Jimenez SA.Varga J, et al.Ann Intern Med. 1992 Jan 15;116(2):140-7. doi: 10.7326/0003-4819-116-2-140.Ann Intern Med. 1992.PMID:1727618Review.
Cited by
- Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.Adachi J, Naito T, Ueno Y, Ogawa Y, Ninomiya I, Tatsuno Y.Adachi J, et al.Arch Toxicol. 1993;67(4):284-9. doi: 10.1007/BF01974348.Arch Toxicol. 1993.PMID:8517785
- L-Tryptophan: Biochemical, nutritional and pharmacological aspects.Sainio EL, Pulkki K, Young SN.Sainio EL, et al.Amino Acids. 1996 Mar;10(1):21-47. doi: 10.1007/BF00806091.Amino Acids. 1996.PMID:24178430
- A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).Silver RM, Ludwicka A, Hampton M, Ohba T, Bingel SA, Smith T, Harley RA, Maize J, Heyes MP.Silver RM, et al.J Clin Invest. 1994 Apr;93(4):1473-80. doi: 10.1172/JCI117125.J Clin Invest. 1994.PMID:8163652Free PMC article.
- Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.Sato F, Hagiwara Y, Kawase Y.Sato F, et al.Arch Toxicol. 1995;69(7):444-9. doi: 10.1007/s002040050197.Arch Toxicol. 1995.PMID:8526739
- Simultaneous determination of L-tryptophan impurities in meat products.Lee DH, Kim YH, Baek M, Heo IK, Shin Y.Lee DH, et al.Amino Acids. 2023 Feb;55(2):173-182. doi: 10.1007/s00726-022-03215-8. Epub 2023 Jan 2.Amino Acids. 2023.PMID:36588144Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources